A Phase 3 interventional study of SHR-2004 injection and SHR-2004 injection in Prevention of Arterial and Venous Thrombosis, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Venous Thrombosis with a site in China — 16 open to participants now, 18 under way, 2 of them phase 3. Venous Thrombosis · China.
Among the 59 studies in Venous Thrombosis with a site in China, this one is the 12th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 3, and was the 50th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →16 of the 59 studies in Venous Thrombosis with a site in China are open now. Recruiting first, the newest first:
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
RenJi Hospital · Sites in China
Ages 18–85
Chinese PLA General Hospital · Sites in China
Ages 18–70 · Healthy volunteers
China-Japan Friendship Hospital · Sites in China
Ages 14+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–100
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 17 · Phase 4 6
First in 2006; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,165 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 360 across the 41 interventional studies, 600 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 3 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Venous Thrombosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04649489Phase 3Jia FanA Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | 2027-08-31 |
| NCT05588284Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityPreservation of Venous Valvular Function After PMT for Acute DVT | 2026-12-30 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT05286710RenJi HospitalRheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Venous Thrombosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-2004 injection · Drug: Enoxaparin sodium injection placebo · Drug: SHR-2004 placebo
Drug: SHR-2004 injection · Drug: Enoxaparin sodium injection placebo · Drug: SHR-2004 placebo
Drug: Enoxaparin sodium injection · Drug: SHR-2004 placebo
SHR-2004 injection in low dose.
SHR-2004 injection in high dose.
Enoxaparin sodium injection.
Enoxaparin sodium injection placebo.
SHR-2004 placebo in low dose.
SHR-2004 placebo in high dose.
Incidence of asymptomatic deep vein thrombosis (DVT)
Time frame: Day 12.
Incidence of non-fatal pulmonary embolism (PE)
Time frame: Day 12.
Adverse events (AEs)
Time frame: Day 65.
Bleeding events
Time frame: Day 12.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Feb 2026, 10 months.
Of 34 phase 3 interventional studies under Venous Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 58. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-2004
Beijing Suncadia Pharmaceuticals Co., Ltd →